(NewsDirect)
Imugene Ltd (ASX:IMU) CEO Leslie Chong tells Proactive that thecompany has dosed the first patients in cohort three of itsintravenous (IV) and intratumoral (IT) monotherapy dose-escalationtrial for novel cancer-killing virus VAXINIA (also known asCF33-hNIS). The City of Hope-developed oncolytic virus has been shownto shrink colon, lung, breast, ovarian and pancreatic cancer tumoursin preclinical laboratory and animal models.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.